Mogamulizumab is a fully humanized and glyco-engineered monoclonal anti-CCR4 antibody used for the treatment of refractory/relapsed ATLL and CTCLs, often resulting in complete remission. The clinical applications of Mogamulizumab are now being extended to solid tumors, exploring the therapeutic effect of regulatory T cell depletion.

Aug 12, 2022 · CCL22/CCR4 signaling activated the intracellular Ca2+/phospholipase C-γ1 (PLC-γ1) axis to stimulate the phosphorylation of DGKα at a tyrosine residue (Tyr335) and promoted the translocation of...

Dec 15, 2022 · Trametinib alleviates anti-CCR4 mAb-induced CTL reduction by downregulating CCR4 expression in CTLs through modulation of TCR signaling. In contrast, trametinib does not affect eTreg...

Mogamulizumab, an anti-CCR4 antibody, reduces the numbers of CCR4+ malignant T cells and CCR4+ Treg cells in cutaneous T-cell lymphoma. ... The CC chemokine receptor 4 (CCR4) is highly expressed on type 2 helper T cells and regulatory T (Treg) cells.

Feb 17, 2023 · The CCR4 interaction with CCL12 activates intracellular signaling that activates various pathways such as NF-Kb, RAS-MAPK, JAK-STAT, P13K-AKT-mTOR, and PLC-Ca 2+, which can regulate angiogenesis, tumor cell proliferation, and apoptosis inhibition. The activation of mitogen-activated protein kinase (MAPK) activates the c-myc transcription factor ...

In the present study, we mainly investigated the role played by the CCL22/CCR4 axis in the maintenance of immune homeostasis during apoptotic cell clearance by splenic CD8 α+ CD103 + DCs.

Nov 4, 2021 · CCR4 is a chemokine receptor mainly expressed by T cells. It is the receptor for two CC chemokine ligands, CCL17 and CCL22. Originally, the expression of CCR4 was described as highly selective for helper T type 2 (Th2) cells.

Jun 10, 2024 · The densitometric analysis revealed that proteins CCR4, Dectin2, PLC-γ2, NFATC2, Nr4a2, and PD-L1 were significantly increased in the CCL22-DC group compared with the DC group, suggesting activation of CCR4 and other signaling molecules by CCL22.

Nov 26, 2020 · CCR4 blockade reduces T reg cell trafficking into mouse tumors. To establish a murine tumor model for assessing whether T reg migration into tumors can be blocked by CCR4 antagonist, we screened multiple tumor models for their CCL17 and …

Two recent studies using the PLC inhibitor U73122 have demonstrated the importance of PLC activation for CXCL12/CXCR4- and CXCL11/ CXCR3-mediated chemotaxis of T cells [25, 45].